Supernus Pharmaceuticals (SUPN) Change in Acquisitions & Divestments (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Change in Acquisitions & Divestments data on file, last reported at $59.2 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 62.09% year-over-year to $59.2 million in Q1 2026; TTM through Mar 2026 was $677.5 million, a 32.13% increase from a year earlier, with the FY2025 full-year figure at $774.5 million, up 55.25% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $59.2 million, up from $39.3 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for SUPN reached as high as $468.6 million in Q3 2025 and fell as low as $17.6 million in Q4 2022.
• Historically, Change in Acquisitions & Divestments has averaged $111.4 million across 5 years, with a median of $75.4 million in 2024.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 95.36% in 2022 and jumped 729.88% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $17.6 million in 2022, then soared by 102.87% to $35.6 million in 2023, then jumped by 273.5% to $133.0 million in 2024, then plunged by 70.43% to $39.3 million in 2025, then soared by 50.62% to $59.2 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $59.2 million in Q1 2026, $39.3 million in Q4 2025, and $468.6 million in Q3 2025.